GlassScriptPhysician profile
Sanjay G Reddy
NPI 1649459595
$4,495.07
in general payments reported to CMS, 2019-2025
40 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $840 · 2021: $745 · 2022: $285 · 2023: $496 · 2024: $495 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.03 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $914.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $526.32 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $336.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $253.49 | 2019-2023 | Belsomra, Steglujan, Steglatro |
| Allergan, INC. | $217.81 | 2019-2020 | |
| Lilly USA, LLC | $211.38 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $175.17 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $169.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $159.97 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $157.12 | 2019-2024 | Farxiga |
| Currax Pharmaceuticals LLC | $138.59 | 2019-2023 | Nexletol, Contrave, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.32 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.51 | 2019-2021 | |
| Abbvie INC. | $108.57 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $108.01 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $71.76 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $66.38 | 2019-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $55.91 | 2019-2024 | |
| Amarin Pharma, INC. | $52.87 | 2019-2020 | |
| Astellas Pharma US INC | $42.92 | 2023-2024 | Veozah |
| Eisai INC. | $42.20 | 2020 | |
| Xeris Pharmaceuticals, INC. | $38.45 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $37.86 | 2023 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $37.36 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $33.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.70 | 2022 | |
| Lundbeck LLC | $29.48 | 2024 | Vyepti |
| Cashflow Solutions, LLC | $29.23 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Dexcom, INC. | $24.94 | 2025 | Dexcom G6 Transmitter |
| Abiomed | $23.10 | 2025 | |
| Abbott Laboratories | $19.15 | 2024 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $17.79 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.36 | 2020 | |
| Insulet Corporation | $16.64 | 2021 | |
| Biogen, INC. | $16.42 | 2021 | |
| Si-Bone, INC. | $16.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.61 | 2019 | |
| Ge Healthcare | $15.29 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.85 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.